ArticleDrug delivery2021
Targeting delivery and minimizing epidermal diffusion of tranexamic acid by hyaluronic acid-coated liposome nanogels for topical hyperpigmentation treatment.
Article in Drug delivery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 28 citations in OpenAlex.
- Hyaluronic Acid-functionalized Hesperidin-loaded Solid Lipid Nanoparticles for Mitigating Oxidative Stress: A Potential Strategy for Radiation-induced Skin Injury.Applied biochemistry and biotechnology · 2026Article
- Progesterone-induced melasma attenuation via tranexamic acid-loaded nano-liposomes: an alternative dermal therapeutic approach.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Multitargeted Modulation of Skin Dullness by HNHT Formulation: Synergistic Inhibition of Melanogenesis, Glycation, and Lipofuscin Deposition.Journal of cosmetic dermatology · 2026Article
- Decrypting the Potential of Lipidic Vesicular System for Delivery Enhancement of Tranexamic Acid in Melasma Hyperpigmentation Treatment.Advanced pharmaceutical bulletin · 2025Review
- Efficacy and Safety Evaluation of Microneedling Combined with Tranexamic Acid-Arbutin Liquid Excipients in the Treatment of Melasma: A Retrospective Study.Clinical, cosmetic and investigational dermatology · 2025Article
- Transdermal Transfersome Nanogels Control Hypertrophic Scar Formation via Synergy of Macrophage Phenotype-Switching and Anti-Fibrosis Effect.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Developments in Emerging Topical Drug Delivery Systems for Ocular Disorders.Current drug research reviews · 2024Review
- Polymeric Nanohydrogel in Topical Drug Delivery System.International journal of nanomedicine · 2024Review
- Polysaccharide-Based Nanogels to Overcome Mucus, Skin, Cornea, and Blood-Brain Barriers: A Review.Pharmaceutics · 2023Review
- Advances in Nanogels for Topical Drug Delivery in Ocular Diseases.Gels (Basel, Switzerland) · 2023Review
- Silk peptide-hyaluronic acid based nanogels for the enhancement of the topical administration of curcumin.Frontiers in chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperpigmentation is a common complaint and distressing problem in dermatology, and tranexamic acid (TA) is an effective treatment agent but limited by the delivery to melanocytes in the epidermis. Herein, a novel TA naogels (named HA/TA-LP), combining the advantages of liposomes and hyaluronic acid (HA), are prepared and assessed for topical hyperpigmentation treatment with targeting delivery and minimizing epidermal diffusion. Morphological characteristics indicate numerous TA-loaded liposomes packed in HA gels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.